[{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ CanariaBio"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ CanariaBio"},{"orgOrder":0,"company":"CanariaBio","sponsor":"CanariaBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Orevogomab","moa":"CA-125 IgC","graph1":"Oncology","graph2":"Phase II","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CanariaBio \/ CanariaBio","highestDevelopmentStatusID":"8","companyTruncated":"CanariaBio \/ CanariaBio"},{"orgOrder":0,"company":"CanariaBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ GSK"},{"orgOrder":0,"company":"CanariaBio","sponsor":"GOG Foundation | IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanariaBio \/ GOG Foundation | IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ GOG Foundation | IQVIA"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanariaBio \/ Veristat","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Veristat"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Raptim Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanariaBio \/ Raptim Research","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Raptim Research"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanariaBio \/ Korean Cancer Study Group","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Korean Cancer Study Group"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MAb-AR20.5","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CanariaBio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by CanariaBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Oregovomab, a murine monoclonal antibody against CA 125, in combination with paclitaxel and carboplatin, is being investigated in patients with newly diagnosed advanced epithelial ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 23, 2024

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 10, 2023

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Specialised Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 10, 2023

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Hikma Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : MAb-AR20.5, an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed ubiquitously on pancreatic cancer cells.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 21, 2023

                          Lead Product(s) : MAb-AR20.5

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Successful enrollment completion of a Phase 2 study of Oregovomab, a murine monoclonal antibody against CA 125, in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurren...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 08, 2023

                          Lead Product(s) : Oregovomab,Niraparib Tosylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 04, 2022

                          Lead Product(s) : Oregovomab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Raptim Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : MAb-B43.13 (oregovomab) is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 28, 2022

                          Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 07, 2022

                          Lead Product(s) : Orevogomab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Yonsei University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 20, 2022

                          Lead Product(s) : Oregovomab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Veristat

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 24, 2021

                          Lead Product(s) : Oregovomab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Korean Cancer Study Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank